



Patient Selection Guidance

Zephyr® Valve Indications for Use¹

Zephyr Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation.

Patient Selection Criteria for the Zephyr Valve Based on Multiple RCTs²⁻⁵

- Diagnosis of emphysema confirmed by CT
- BMI <35 kg/m²
- Stable with ≤20mg prednisone (or equivalent) daily
- RV ≥175% predicted (≥200% if homogeneous)
- FEV₁ 15-45% predicted
- TLC ≥100% predicted
- 6MWD 100-500m (150-500m if homogeneous)
- Not actively smoking (for at least 4 months)
- Target lobe with little to no collateral ventilation (as measured by StratX® and/or Chartis® Assessment)

Patient Exclusion Criteria for the Zephyr Valve Based on Multiple RCTs²⁻⁵

- Prior lung transplant, LVRS, median sternotomy, or lobectomy
- Congestive heart failure: Left Ventricular Ejection Fraction <45%; unstable cardiac arrhythmia, myocardial infarction, or stroke
- Known allergies to Nitinol, Nickel, Titanium, or Silicone
- Large bullae >30% of either lung
- Medical conditions or other circumstances make it likely that the patient will be unable to complete the preoperative and postoperative pulmonary diagnostic and therapeutic program required for the procedure
- Contraindications for bronchoscopy; patient characteristics that may carry a high risk for postoperative morbidity and/or mortality
- Severe hypercapnia (PaCO₂ ≥50 mm Hg on room air) and/or severe hypoxemia (PaO₂ ≤45 mm Hg on room air)
- Uncontrolled pulmonary hypertension (sPAP >45 mm Hg)

Zephyr Valve Patient Work-Up

Medical history

- Diagnosis of emphysema
- BMI <35 kg/m²
- Stable with ≤20mg prednisone (or equivalent) daily
- Non-smoking
- Collect any available imaging and lung function studies

Pulmonary function tests (post-bronchodilator)

- Spirometry (FEV₁ 15-45% predicted)
- Body plethysmography (RV ≥175%, TLC ≥100%)

Arterial blood gas levels collected on room air

- Rule out severe hypercapnia (PaCO₂ ≥50 mm Hg)
- Rule out severe hypoxemia (PaO₂ ≤45 mm Hg)

6MWD (100m-500m)

Imaging

- High-Resolution CT Inspiration scan (TLC view) with a slice thickness ≤1.5 mm. Ensure all files are in standard .DICOM format*
- Upload to StratX
- Perfusion Scan (if needed)

Echocardiogram

- Rule out congestive heart failure (LVEF <45%)
- Rule out uncontrolled pulmonary hypertension (sPAP >45 mm Hg)

Recommended

- Vaccinations (pneumococcal and flu)
- Pulmonary Rehab

Brief Statement: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV₁ <15% of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.

Brief Statement: The Chartis® System is indicated for use by bronchoscopists during a bronchoscopy in adult patients with emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD), in a bronchoscopy suite. The system, composed of the Chartis Catheter and Chartis Console, is designed to measure pressure and flow in order to calculate resistance to airflow and quantify collateral ventilation in isolated lung compartments. The Chartis Catheter is used through the working channel of a bronchoscope and connects to the Chartis Console. The Chartis Console is capital equipment that is reusable and displays the patient information. The Chartis System is contraindicated in the presence of active infection or major bleeding diathesis. There are no known interfering substances. Use is restricted to a trained physician. Prior to use, please reference the Chartis System Instructions for Use/User Manual for more information on indications, contraindications, warnings, all precautions, and adverse events.

*Do not upload Scout scan, Dose Report, or any other study series which has less than 50 .DICOM files. These smaller series scans often contain PHI and will be rejected, requiring the site to re-upload the scans.

Caution: Federal law restricts this device to sale by or on the order of a physician.

- Zephyr Valve IFU
- Criner, GJ, Sue, R, Wright, S, Dransfield, M, Rivas-Perez H, Wiese, T, Sciurba, FC, Shah, PL, Wahidi, MM, de Oliveira, HG, & Morrissey, B. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med, 2018; 198(9), 1151–1164 and data on file for Zephyr Valve.
- Kemp, SV, Slebos, DJ, Kirk, A, Kornaszewska, M, Carron, K, Ek, L, & Briault, A. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med, 2017; 196(12), 1535–1543.
- Valipour, A, Slebos, DJ, Herth, F, Darwiche, K, Wagner, M, Ficker, JH, & Eberhardt, R. Endobronchial valve therapy in patients with homogeneous emphysema. Results from the IMPACT study. Am J Respir Crit Care Med, 2016; 194(9), 1073–1082 and data on file.
- Klooster, K, ten Hacken, NH, Hartman, JE, Kerstjens, HA, van Rikxoort, EM, & Slebos, DJ. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med, 2015; 373(24), 2325–2335.

Pulmonx Corporation

700 Chesapeake Drive
Redwood City, CA 94063

© 2020 Pulmonx Corporation or its affiliates. All rights reserved.
All trademarks are property of their respective owners.
US-EN-190-v2 – August 2020 Zephyr Patient Selection Guidance

